☰

Bryan C. Fuchs, Ph.D. - Publications

Affiliations: 
2005 Saint Louis University, St. Louis, MO, United States 
Area:
Cell Biology, Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

64 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, Hu JK, Schaub JR, Ho SS, Rao V, Marlow MM, Turner SM, Sedki M, Pantano L, Ghoshal S, ... ... Fuchs BC, et al. Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Science Translational Medicine. 12. PMID 32817366 DOI: 10.1126/Scitranslmed.Aay8798  0.374
2020 Erstad DJ, Sojoodi M, Taylor MS, Clavijo Jordan V, Farrar CT, Axtell AL, Rotile NJ, Jones C, Graham-O'Regan KA, Ferreira DS, Michelakos T, Kontos F, Chawla A, Li S, Ghoshal S, ... ... Fuchs BC, et al. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and is Measurable with Collagen-Targeted Molecular MRI. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32611647 DOI: 10.1158/1078-0432.Ccr-18-1359  0.316
2020 Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, Pendem S, Newstrom D, Brockett R, Mikaelian I, Kusam S, ... ... Fuchs BC, et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. Journal of Hepatology. PMID 32376414 DOI: 10.1016/J.Jhep.2020.04.037  0.328
2020 Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, Kim RS, Lauwers GY, Lanuti M, Hoshida Y, Tanabe KK, Fuchs BC. Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prevention Research (Philadelphia, Pa.). PMID 32253266 DOI: 10.1158/1940-6207.Capr-19-0383  0.351
2020 Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, ... ... Fuchs BC, et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut. PMID 32217639 DOI: 10.1136/Gutjnl-2019-318918  0.336
2019 Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, ... ... Fuchs BC, et al. HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology. PMID 30836093 DOI: 10.1053/J.Gastro.2019.02.038  0.304
2018 Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 30367397 DOI: 10.1007/S11605-018-4004-6  0.308
2018 Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, Fujiwara N, Leong V, Houde VP, Anagnostopoulos AE, Wang A, Broadfield LA, Ford RJ, Foster RA, ... ... Fuchs BC, et al. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. Cell Metabolism. PMID 30244972 DOI: 10.1016/J.Cmet.2018.08.020  0.381
2018 Yoo B, Fuchs BC, Medarova Z. New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology. 8: 258. PMID 30042926 DOI: 10.3389/Fonc.2018.00258  0.304
2018 Kim BM, Abdelfattah AM, Vasan R, Fuchs BC, Choi MY. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis. Scientific Reports. 8: 7499. PMID 29760499 DOI: 10.1038/S41598-018-25699-9  0.333
2018 Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer. PMID 29663340 DOI: 10.1002/Cncr.31257  0.329
2018 Qu C, Zheng D, Li S, Liu Y, Lidofsky A, Holmes JA, Chen J, He L, Wei L, Liao Y, Yuan H, Jin Q, Lin Z, Hu Q, Jiang Y, ... ... Fuchs BC, et al. Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis. Hepatology (Baltimore, Md.). PMID 29537660 DOI: 10.1002/Hep.29881  0.389
2018 Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC, Hoshida Y. In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Experimental & Molecular Medicine. 50: e419. PMID 29303513 DOI: 10.1038/Emm.2017.164  0.332
2018 Erstad DJ, Ramsay I, Sojoodi M, Farrar C, Rotile NJ, Li S, Ghoshal S, Michael L, Caravan P, Tanabe KK, Fuchs BC, Gale E. Abstract 659: A novel manganese MRI contrast agent (PyC3A) for the evaluation of hepatic neoplasms Cancer Research. 78: 659-659. DOI: 10.1158/1538-7445.Am2018-659  0.336
2017 Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, de Galarreta MR, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, ... ... Fuchs BC, et al. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29157977 DOI: 10.1016/J.Nano.2017.11.004  0.368
2017 Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, et al. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing Disulfiram. Cancer Letters. PMID 28864067 DOI: 10.1016/J.Canlet.2017.08.028  0.303
2017 Erstad DJ, Tager AM, Hoshida Y, Fuchs BC. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Molecular & Cellular Oncology. 4: e1311827. PMID 28616586 DOI: 10.1080/23723556.2017.1311827  0.379
2017 Asano T, Yamada S, Fuchs BC, Takami H, Hayashi M, Sugimoto H, Fujii T, Tanabe KK, Kodera Y. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma. International Journal of Oncology. PMID 28350091 DOI: 10.3892/Ijo.2017.3937  0.365
2017 Chen JY, Newcomb B, Zhou C, Pondick JV, Ghoshal S, York SR, Motola DL, Coant N, Yi JK, Mao C, Tanabe KK, Bronova I, Berdyshev EV, Fuchs BC, Hannun Y, et al. Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. Scientific Reports. 7: 44867. PMID 28322247 DOI: 10.1038/Srep44867  0.345
2017 Hicks DF, Goossens N, Blas-García A, Tsuchida T, Wooden B, Wallace MC, Nieto N, Lade A, Redhead B, Cederbaum AI, Dudley JT, Fuchs BC, Lee YA, Hoshida Y, Friedman SL. Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports. 7: 42563. PMID 28256512 DOI: 10.1038/Srep42563  0.359
2017 Li S, Ghoshal S, Arora G, Erstad DJ, Lanuti M, Tanabe KK, Fuchs BC. Abstract 5248: Pioglitazone prevents hepatocellular carcinoma development in a rat model of cirrhosis Cancer Research. 77: 5248-5248. DOI: 10.1158/1538-7445.Am2017-5248  0.346
2016 Kim RS, Hasegawa D, Goossens N, Tsuchida T, Athwal V, Sun X, Robinson CL, Bhattacharya D, Chou HI, Zhang DY, Fuchs BC, Lee Y, Hoshida Y, Friedman SL. The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. Scientific Reports. 6: 39342. PMID 27996033 DOI: 10.1038/Srep39342  0.375
2016 Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, ... ... Fuchs BC, et al. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell. 30: 879-890. PMID 27960085 DOI: 10.1016/J.Ccell.2016.11.004  0.366
2016 Ghoshal S, Fuchs BC, Tanabe KK. STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. Hepatobiliary Surgery and Nutrition. 5: 201-3. PMID 27275460 DOI: 10.21037/Hbsn.2016.03.02  0.332
2016 DePeralta DK, Wei L, Ghoshal S, Schmidt B, Lauwers GY, Lanuti M, Chung RT, Tanabe KK, Fuchs BC. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer. PMID 26914713 DOI: 10.1002/Cncr.29912  0.37
2016 Wei L, Harriman G, Ghoshal S, Moaven O, Greenwood J, Bhat S, Westlin WF, Harwood HJ, Kapeller R, Tanabe KK, Fuchs BC. Abstract 3781: Combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma Cancer Research. 76: 3781-3781. DOI: 10.1158/1538-7445.Am2016-3781  0.358
2015 Schmidt B, Wei L, DePeralta DK, Hoshida Y, Tan P, Sun X, Sventek JP, Lanuti M, Tanabe KK, Fuchs BC. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. International Journal of Cancer. Journal International Du Cancer. PMID 26481559 DOI: 10.1002/Ijc.29893  0.365
2015 Fuchs BC, Hoshida Y, Tanabe KK. Reply: To PMID 24677197. Hepatology (Baltimore, Md.). 61: 729-30. PMID 24799327 DOI: 10.1002/Hep.27208  0.346
2015 Moaven O, Wei L, Harriman G, Greenwood J, Bhat S, Westlin WF, Harwood HJ, Kapeller R, DePeralta DK, Tanabe KK, Fuchs BC. Abstract 4452: Liver selective acetyl-CoA carboxylase inhibition by ND-654 improves survival in cirrhotic rats with hepatocellular carcinoma Cancer Research. 75: 4452-4452. DOI: 10.1158/1538-7445.Am2015-4452  0.332
2015 Westlin W, Harwood H, DePeralta D, Moaven O, Wei L, Greenwood J, Bhat S, Fuchs B, Kapeller R, Harriman G. LP30 : Liver-directed allosteric inhibitors of acetyl-coa carboxylase favorably impact pathophysiology in the progression from nafld to nash and hepatocellular carcinoma, including hepatic steatosis, inflammation, and fibrosis Journal of Hepatology. 62: S279. DOI: 10.1016/S0168-8278(15)30184-7  0.326
2014 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of Hepatology. 61: S79-90. PMID 25443348 DOI: 10.1016/J.Jhep.2014.07.010  0.334
2014 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Current Pathobiology Reports. 2: 245-256. PMID 25396099 DOI: 10.1007/S40139-014-0061-Z  0.306
2014 Yamada S, Okumura N, Wei L, Fuchs BC, Fujii T, Sugimoto H, Nomoto S, Takeda S, Tanabe KK, Kodera Y. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. Annals of Surgical Oncology. 21: 3882-90. PMID 24833103 DOI: 10.1245/S10434-014-3779-2  0.319
2014 Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, Kuroda T, Lanuti M, Schmitt AD, Gupta S, Crenshaw A, Onofrio R, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 59: 1577-90. PMID 24677197 DOI: 10.1002/Hep.26898  0.375
2014 Murai T, Yamada S, Fuchs BC, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Tanabe KK, Kodera Y. Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer. Journal of Surgical Oncology. 109: 684-9. PMID 24453058 DOI: 10.1002/Jso.23564  0.31
2014 Schmidt B, Wei L, DePeralta DK, Hoshida Y, Lanuti M, Tanabe KK, Fuchs BC. Abstract 5435: Molecular subclasses of human hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition Cancer Research. 74: 5435-5435. DOI: 10.1158/1538-7445.Am2014-5435  0.37
2014 DePeralta DK, Wei L, Harriman G, Greenwood J, Bhat S, Westlin W, Harwood HJ, Kapeller R, Tanabe KK, Fuchs BC. Abstract 1427: Liver selective Acetyl-CoA Carboxylase inhibition by ND-654 decreases hepatocellular carcinoma development in cirrhotic rats Cancer Research. 74: 1427-1427. DOI: 10.1158/1538-7445.Am2014-1427  0.384
2014 DePeralta D, Wei L, Lauwers G, Fuchs B, Tanabe K. Metformin Inhibits Hepatocellular Carcinoma in a Cirrhosis Model Journal of Surgical Research. 186: 633. DOI: 10.1016/J.Jss.2013.11.645  0.306
2014 DePeralta DK, Wei L, Harriman G, Greenwood J, Westlin WF, Harwood J, Bhat S, Kapeller R, Fuchs BC, Tanabe KK. Liver Selective Acetyl-CoA Carboxylase Inhibition Inhibits Hepatocellular Carcinoma in a Cirrhosis Model Journal of the American College of Surgeons. 219: S23-S24. DOI: 10.1016/J.Jamcollsurg.2014.07.045  0.329
2013 Suenaga M, Yamada S, Fujii T, Fuchs BC, Okumura N, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Takeda S, Hayashi K, et al. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Oncotargets and Therapy. 6: 1805-12. PMID 24363559 DOI: 10.2147/Ott.S53625  0.305
2013 Wei L, Hoshida Y, Bain G, Swaney J, Lauwers GY, Schaefer EA, Yamada S, Lanuti M, Chung RT, Tanabe KK, Fuchs BC. Abstract 177: Inhibition of the autotaxin-lysophosphatidic acid (ATX-LPA) pathway for chemoprevention of hepatocellular carcinoma. Cancer Research. 73: 177-177. DOI: 10.1158/1538-7445.Am2013-177  0.396
2013 Murai T, Yamada S, Fuchs BC, Fujii T, Fujiwara M, Tanabe KK, Kodera Y. Abstract 1473: Epithelial to mesenchymal transition predicts prognosis In clinical gastric cancer. Cancer Research. 73: 1473-1473. DOI: 10.1158/1538-7445.Am2013-1473  0.305
2013 Mehta AK, Bettermann K, Lederer EM, Ernst C, Kessler SM, Kojima K, Chen X, Hoshida Y, Fuchs BC, Svendova V, Schimek MG, Mach M, Speicher MR, Stojakovic T, Magin TM, et al. Abstract A38: Steatohepatitis-associated hepatocellular carcinoma: Evidence of a keratin-based disease. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A38  0.331
2013 Schmidt B, Deperalta DK, Wei L, Hoshida Y, Tanabe KK, Fuchs BC. Molecular subclasses of human hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition Journal of the American College of Surgeons. 217. DOI: 10.1016/J.Jamcollsurg.2013.07.307  0.3
2013 DePeralta DK, Fuchs BC, Yamada S, Fujii T, Lauwers GY, Lanuti M, Tanabe KK. Epithelial growth factor receptor inhibition effectively inhibits liver fibrosis and hepatocellular carcinoma Journal of the American College of Surgeons. 217: S20. DOI: 10.1016/J.Jamcollsurg.2013.07.030  0.339
2012 Hoshida Y, Fuchs BC, Tanabe KK. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current Cancer Drug Targets. 12: 1129-59. PMID 22873223 DOI: 10.2174/156800912803987977  0.339
2012 Yamada S, Fujii T, Wei L, Hoshida Y, Lauwers GY, Schmitt AD, Lanuti M, Tanabe KK, Fuchs BC. Abstract 5427: EGCG prevents hepatocellular carcinoma development in a diethylnitrosamine-induced rat model Cancer Research. 72: 5427-5427. DOI: 10.1158/1538-7445.Am2012-5427  0.366
2012 Schmitt AD, Fuchs BC, Wei L, Tanabe KK, Lanuti M. Abstract 4610: Characterizing TGFβ1-inducible EMT models in NSCLC helps define critical EMT-associated genes for therapeutic targeting Cancer Research. 72: 4610-4610. DOI: 10.1158/1538-7445.Am2012-4610  0.348
2012 Okumura N, Yamada S, Fuchs BC, Fujii T, Sugimoto H, Nomoto S, Takeda S, Tanabe KK, Kodera Y, Nakao A. Abstract 3402: Clinical implication of epithelial to mesenchymal transition (EMT) in hepatocellular carcinoma Cancer Research. 72: 3402-3402. DOI: 10.1158/1538-7445.Am2012-3402  0.342
2012 Fujii T, Yamada S, Okumura N, Fuchs BC, Suenaga M, Nakayama G, Sugimoto H, Takeda S, Tanabe KK, Kodera Y. Clinical Implication of Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)34251-4  0.352
2011 Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 141: 141-9. PMID 21440548 DOI: 10.1053/J.Gastro.2011.03.045  0.301
2011 Schmitt AD, Fuchs BC, McGinn CM, Goodwin JM, Tanabe KK, Lanuti M. Abstract 3366: Epithelial to mesenchymal transition mediates sensitivity to viral oncolysis in vitro and in a xenograft flank tumor model of non small cell lung cancer Cancer Research. 71: 3366-3366. DOI: 10.1158/1538-7445.Am2011-3366  0.321
2010 Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, Lanuti M, Tanabe KK. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. Bmc Gastroenterology. 10: 79. PMID 20618941 DOI: 10.1186/1471-230X-10-79  0.36
2010 Fuchs BC, Kuroda T, Yamada S, McGinn CM, Schmitt A, Lanuti M, Tanabe KK. Abstract 598: EMT and nectin-1 mediate sensitivity to HSV-1 oncolysis in human HCC cell lines Cancer Research. 70: 598-598. DOI: 10.1158/1538-7445.Am10-598  0.346
2010 Fuchs BC, Hoshida Y, Fujii T, Lauwers GY, McGinn CM, Yamada S, Kuroda T, Lanuti M, Gupta S, Crenshaw A, Onofrio R, Taylor B, Winckler W, Golub TR, Tanabe KK. Abstract 2925: Gene expression analysis to monitor erlotinib prevention of hepatocellular transformation during cirrhosis Cancer Research. 70: 2925-2925. DOI: 10.1158/1538-7445.Am10-2925  0.364
2010 Schmitt AD, Fuchs BC, McGinn C, Kuroda T, Goodwin JM, Tanabe KK, Lanuti M. Abstract 2315: Influence of epithelial to mesenchymal transition on viral oncolysis in non small cell lung cancer Cancer Research. 70: 2315-2315. DOI: 10.1158/1538-7445.Am10-2315  0.331
2008 Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Research. 68: 2391-9. PMID 18381447 DOI: 10.1158/0008-5472.Can-07-2460  0.374
2008 Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama. 299: 53-60. PMID 18167406 DOI: 10.1001/Jama.2007.65  0.309
2007 Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. American Journal of Physiology. Cell Physiology. 293: C55-63. PMID 17329400 DOI: 10.1152/Ajpcell.00330.2006  0.627
2006 Fuchs BC, Bode BP. Stressing out over survival: glutamine as an apoptotic modulator. The Journal of Surgical Research. 131: 26-40. PMID 16154153 DOI: 10.1016/J.Jss.2005.07.013  0.674
2005 Onan MC, Fisher JS, Ju JS, Fuchs BC, Bode BP. Type I diabetes affects skeletal muscle glutamine uptake in a fiber-specific manner. Experimental Biology and Medicine (Maywood, N.J.). 230: 606-11. PMID 16179728 DOI: 10.1177/153537020523000902  0.644
2005 Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Seminars in Cancer Biology. 15: 254-66. PMID 15916903 DOI: 10.1016/J.Semcancer.2005.04.005  0.693
2004 Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. American Journal of Physiology. Gastrointestinal and Liver Physiology. 286: G467-78. PMID 14563674 DOI: 10.1152/Ajpgi.00344.2003  0.701
2002 Bode BP, Fuchs BC, Hurley BP, Conroy JL, Suetterlin JE, Tanabe KK, Rhoads DB, Abcouwer SF, Souba WW. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. American Journal of Physiology. Gastrointestinal and Liver Physiology. 283: G1062-73. PMID 12381519 DOI: 10.1152/Ajpgi.00031.2002  0.698
Show low-probability matches.